TrialBreast cancer research : BCR2025

Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial.

Jaqueline Munhoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.